Beclometasone


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Mild to moderate ulcerative colitis As modified-release tab: 5 mg once daily in the morning. Max: 4 wk. Topical Corticosteroid-responsive dermatoses As 0.025% cream: Apply a thin film to affected area(s) 1-3 times daily, or as directed. Nasal Treatment and prophylaxis of allergic and non-allergic rhinitis As spray: 100 mcg into each nostril bid, or 50 mcg in each nostril 3-4 times/day. Max: 400 mcg/day. 50 mcg in each nostril bid as prophylaxis. Inhalation Asthma prophylaxis As aerosol or dry powd inhaler: Initial: Mild: 100-200 mcg/day. Moderate: 200-400 mcg/day. Severe: 400-800 mcg/day. Doses are given in 2 divided doses. Usual maintenance dose: 400-800 mcg/day in 2 divided doses. Max: 800 mcg/day (up to 2 mg in severe cases) in divided doses.
Contraindications
As primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures (inhalation).
Special Precautions
Patient w/ bacterial (e.g. active or quiescent pulmonary TB), fungal, parasitic, and viral (e.g. chickenpox, measles, ocular herpes simplex) infection, DM, gastro-duodenal ulcer, serious arterial HTN, myasthenia gravis, MI, osteoporosis, hypoadrenalism, glaucoma, cataract, seizure disorder, depression, previous steroid-related psychosis, recent nasal septal ulcers, trauma, and surgery. Renal and hepatic (e.g. cirrhosis) impairment. Childn, Pregnancy and lactation. Patient Counselling Rinse mouth thoroughly after inhalation. Monitoring Parameters Monitor growth annually during long term use in childn. Assess for ocular changes, signs and symptoms of adrenal insufficiency, and oral candidiasis.
Adverse Reactions
Oral candidiasis, hoarseness, cough, epistaxis, irritation and dryness of nose and throat, unpleasant taste and smell, nasopharyngitis, rhinitis, sneezing, paradoxical bronchospasm w/ wheezing, dyspnoea; hypersensitivity (e.g. rash, urticaria, pruritus, erythema, angioedema); impaired wound healing; headache, vertigo, tremor; adrenal suppression. Rarely, Cushing's syndrome, decreased bone mineral density, psychomotor hyperactivity, aggression, irritability, anxiety, depression, sleep disorder, suicidal ideation.
ATC Classification
A07EA07 - beclometasone ; Belongs to the class of corticosteroids acting locally. Used in the treatment of intestinal inflammation.
R01AD01 - beclometasone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
D07AC15 - beclometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
R03BA01 - beclometasone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Disclaimer: This information is independently developed by CIMS based on beclometasone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in